New Delhi:Sun Pharma has kept its options open on enhancing its manufacturing footprint in the U.S., even as the U.S. administration's 100% tariff on branded and patented medicines has created uncertainty for global drugmakers. During an analyst call, Richard Ascroft, CEO for Sun Pharma’s North America business, said the company already has a manufacturing footprint in the U.S.. Read also:Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide Sun Pharma is a specialty generics company with a presence in specialty, generics and consumer healthcare products. Sun Pharma’s global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. Its manufacturing facilities are spread across six continents. Read also:Sun Pharma appoints Jeremy Allen as Vice President, Corporate Affairs for North America
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!